Gilead Sciences, Inc. (NASDAQ:GILD) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, everyone, and welcome to Gilead's Second Quarter 2024 Earnings Conference Call. My name is Rebecca, and I'll be your host for today.
Gilead Sciences Inc. (GILD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Sigma Advisors John Overdeck And David Siegel | 6,255,700 | $429,203,577 | +24% | 0.95% |
| 2. | Renaissance Technologies Jim Simons | 5,057,598 | $347,001,799 | +18% | 0.58% |
| 3. | D E Shaw D. E. Shaw | 3,338,252 | $229,037,470 | +195% | 0.21% |
| 4. | Millennium Management Israel Englander | 2,540,190 | $174,282,436 | +357% | 0.08% |
| 5. | AQR Capital Management Cliff Asness | 2,053,073 | $140,861,363 | -39% | 0.21% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $99.92 | 10,000 | Director | 88,173 | 2015-02-06 | Filing | |
| $43.05 | 10,000 | Director | 69,458 | 2013-02-28 | Filing | |
| $44.00 | 10,000 | Director | 26,097 | 2012-02-22 | Filing | |
| $38.60 | 8,704 | Director | 12,800 | 2010-05-04 | Filing | |
| $38.59 | 4,096 | Director | 4,096 | 2010-05-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $84.50 | 21,246 | Officer | 102,189 | 2024-09-12 | Filing | |
| $83.25 | 13,432 | Officer | 78,127 | 2024-09-12 | Filing | |
| $84.23 | 15,925 | Officer | 91,559 | 2024-09-12 | Filing | |
| $78.03 | 9,513 | Officer | 105,466 | 2024-08-28 | Filing | |
| $73.98 | 5,490 | Officer | 114,979 | 2024-08-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 122,793,011 | $9,947,461,818 | 0.25% | |
| 2. | 111,822,428 | $9,058,734,893 | 0.19% | |
| 3. | 83,364,123 | $6,753,349,838 | 1.2% | |
| 4. | 59,657,126 | $4,832,824,186 | 1.18% | |
| 5. | 59,536,425 | $4,823,045,789 | 0.23% |
News See All
Should You Hold Gilead Sciences (GILD)?
Parnassus Investments, an investment management company, released the “Parnassus Value Equity Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here.
Hedge Funds are Bullish on This Gene Therapy Stock
Gene therapy involves treating illnesses by modifying, replacing, or supplementing faulty or missing genes responsible for a disease.
9 Best Gene Therapy Stocks to Buy Now
In this article, we will be discussing the best gene therapy stocks to buy now. Before we move on to our list, let's take a look at the market outlook for gene therapies and understand the reasons behind...
23 Most Profitable Stocks of the Last 12 Months
In this article, we discuss the 23 most profitable stocks of the last 12 months.
Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Call Transcript
Gilead Sciences, Inc. beats earnings expectations. Reported EPS is $-1.32, expectations were $-1.49. Gilead Sciences, Inc.
5 Best Depressed Stocks To Buy in 2024
Biogen Inc (NASDAQ:BIIB) shares are down 27% over the past one year.
5 Best High-Dividend Stocks to Buy Right Now
In this article, we discuss 5 best high-dividend stocks to buy right now.
12 Most Profitable Biotech Stocks To Invest In
In this piece, we will take a look at the 12 most profitable biotech stocks to invest in.
15 Best NASDAQ Dividend Stocks To Buy
In this article, we discuss 15 best NASDAQ dividend stocks to buy.
Billionaire Hedge Funds
